VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met… CISION PRNewswireApril 24, 2025
Press ReleaseMedit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics SEOUL, South Korea, April 25, 2025 /PRNewswire/ — Medit, a global leader… CISION PRNewswireApril 24, 2025
NYSE Content Advisory: Midday market update + NYSE President congratulates new SEC Chair Paul Atkins NEW YORK, April 24, 2025 /PRNewswire/ — The New York Stock Exchange… CISION PRNewswireApril 24, 2025
Press ReleasePrimo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine. TAIPEI, April 24, 2025 /PRNewswire/ — Primo Biotechnology Co., Ltd. ("Primo") proudly… CISION PRNewswireApril 24, 2025
MicroAlgo Inc. Develops Classical Boosted Quantum Optimization Algorithm (CBQOA) SHENZHEN, China, April 24, 2025 /PRNewswire/ — MicroAlgo Inc. (the "Company" or… CISION PRNewswireApril 24, 2025
Press ReleaseNota AI Named to the 2025 CB Insights' List of the 100 Most Innovative AI Startups Nota AI demonstrates global technological leadership in ‘AI Infrastructure: Accelerated Computing &… CISION PRNewswireApril 24, 2025
Press ReleaseAbu Dhabi Pioneers Collaborative Approach to Responsible AI in Healthcare at Health Leaders Roundtable Held during Abu Dhabi Global Health Week, the roundtable united global health… CISION PRNewswireApril 24, 2025
Webull Announces Brand Partnership with Tampa Bay Rays ST PETERSBURG, Fla., April 24, 2025 /PRNewswire/ — Webull (NASDAQ: BULL), an online… CISION PRNewswireApril 24, 2025
